All In Biotech

Drug Trial Radar · NCT06538662

An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations

A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Efficacy and Safety Study of FID 123320 Ophthalmic Solution for the Reduction of Ocular Redness in Pediatric and Adult Populations

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 284 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

284

Actual

Start

Oct 7, 2024

Primary completion

Jan 27, 2025

Study completion Apr 3, 2025

Sponsor

Lead sponsor
Alcon ResearchIndustry
Sponsor type
Industry
First posted
Aug 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of FID 123320 Ophthalmic Solution (Apraclonidine HCl 0.125%) compared to Vehicle for relieving redness of the eye due to minor eye irritations in pediatric and adult populations.

Conditions

  • Ocular Redness
  • Eye Irritation

Interventions

  • Apraclonidine Hydrochloride Ophthalmic SolutionDrug

    Investigational ophthalmic solution applied topically to the eye with a dropper bottle

  • VehicleDrug

    Vehicle (inactive ingredients) applied topically to the eye with a dropper bottle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Least Squares Mean Change From Baseline in Investigator-Assessed Ocular Redness at 15 Minutes Post-Instillation on Day 1 - Adult CohortTime frame: Baseline (Day 1 pre-instillation); Minute 15 (Day 1 post-instillation)
  2. Least Squares Mean Change From Baseline in Investigator-Assessed Ocular Redness at 10 Hours (600 Minutes) Post-Instillation on Day 1 - Adult CohortTime frame: Baseline (Day 1 pre-instillation); Hour 10 (600 minutes) (Day 1 post-instillation)
  3. Least Squares Mean Change From Baseline in Investigator-Assessed Ocular Redness at 1 Hour (60 Minutes) Post-Instillation on Day 1 - Pediatric Cohort (12-17 Years)Time frame: Baseline (Day 1 pre-instillation); Hour 1 (60 minutes) (Day 1 post-instillation)

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Eye Research Foundation

    Newport Beach, California

  • Vision Institute

    Colorado Springs, Colorado

  • Butchertown Clinical Trials

    Louisville, Kentucky

  • Andover Eye Associates

    Andover, Massachusetts

  • NC Eye Associates, OD, PLLC

    Apex, North Carolina

  • CORE, Inc.

    Shelby, North Carolina

  • Total Eye Care PA

    Memphis, Tennessee

  • Advancing Vision Research, LLC

    Smyrna, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.